The inactivation of tumour suppressor genes is a key step in cancer development, and is usually achieved by homozygous loss. In prostate cancer, however, large genomic regions are often hemizygously lost, which complicates the identification of putative tumour suppressors in these regions. Here, we develop Epi2Hit, an...
Daria Kiriy, Francesco Favero, C. Gerhäuser et al.· Nature Communications· 0 citations
Prostate cancer follows a long and heterogeneous disease course with incompletely understood aetiology1. Here we dissect the mutational processes shaping the genomes of 959 donors from the Pan Prostate Cancer Group and assess their clinical relevance. By integrating de novo extracted single-base substitution, insertion...
A. Gruber, A. Olsen, Bárbara Hernando et al.· Nature· 2 citations
TFiT (tumor-reactive features in T cells), a transcriptional classifier that identifies tumor-reactive T cells and stratifies immunotherapy, but not chemotherapy, response across independent MM and AML cohorts, supporting its specificity for T cell-mediated tumor control.
N. Kehl, T. Wagner, Simon Steiger et al.· Cancer Cell· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
